1 July 2016 in OncoImmunology
HER2-directed therapies are less effective in patients with ERpos compared to ERneg breast cancer, possibly reflecting bidirectional activation between HER2 and estrogen signaling pathways. We investigated dual blockade using anti-HER2 vaccination and anti-estrogen therapy in HER2pos/ERpos early breast cancer patients. In pre-clinical studies of HER2pos breast cancer cell lines, ERpos cells were partially resistant to CD4+ Th1 cytokine-induced metabolic suppression compared with ERneg cells. The addition of anti-estrogen treatment significantly enhanced cytokine sensitivity in ERpos, but not ERneg, cell lines. In two pooled phase-I clinical trials, patients with HER2pos early breast cancer were treated with neoadjuvant anti-HER2 dendritic cell vaccination; HER2pos/ERpos patients were treated with or without concurrent anti-estrogen therapy. The anti-HER2 Th1 immune response measured in the peripheral blood significantly increased following vaccination, but was similar across the three treatment groups (ERneg vaccination alone, ERpos vaccination alone, ERpos vaccination + anti-estrogen therapy). In the sentinel lymph nodes, however, the anti-HER2 Th1 immune response was significantly higher in ERpos patients treated with combination anti-HER2 vaccination plus anti-estrogen therapy compared to those treated with anti-HER2 vaccination alone. Similar rates of pathologic complete response (pCR) were observed in vaccinated ERneg patients and vaccinated ERpos patients treated with concurrent anti-estrogen therapy (31.4% vs. 28.6%); both were significantly higher than the pCR rate in vaccinated ERpos patients who did not receive anti-estrogen therapy (4.0%, p = 0.03). Since pCR portends long-term favorable outcomes, these results support additional clinical investigations using HER2-directed vaccines in combination with anti-estrogen treatments for ERpos/HER2pos DCIS and invasive breast cancer.
1 August 2021 in Journal of Laparoendoscopic & Advanced Surgical Techniques
Crohn's disease (CD) is a pan-intestinal disease of the gastrointestinal tract characterized by inflammatory, penetrating, and fibrostenotic phenotypes. Fibrostenotic stricture formation, without inflammatory or penetrating disease, is a common complication in CD, primarily affecting the small intestine and leading to small bowel obstruction. Because there is no medical therapy that prevents or reverses stricturing disease, endoscopic and surgical treatments are the mainstays of treatment, indicated to palliate symptoms and treat the complications. Endoscopic approaches include dilation, stricturotomy, and endoscopic stenting. Surgical options include resection, intestinal bypass, and various strictureplasty techniques. In this article, we will focus on the treatment of stricturing CD: specifically, the considerations important in choosing between different treatment options and technical tips to deal with complicated disease.
26 August 2026 in Clinical Cancer Research
Purpose: Effective immunotherapy for mismatch repair–proficient (pMMR) colorectal cancer is lacking. We examined the safety and efficacy of the novel next-generation immune activator/Fc-enhanced cytotoxic T lymphocyte–associated protein 4 (CTLA-4) inhibitor botensilimab (BOT) plus programmed cell death protein 1 (PD-1) inhibitor balstilimab (BAL) in the neoadjuvant setting for patients with resectable colorectal cancer. Patients and Methods: Patients 18 years of age or older with nonmetastatic colorectal cancer awaiting surgical resection were eligible. BOT/BAL was administered followed by surgical resection. In cohort A, patients received BOT 75 mg on day 1 and BAL 240 mg on days 1 and 15; in cohorts B/C, patients received two additional BAL doses (on days 29 and 43). The primary study objectives were safety, feasibility (based on surgery delay), and pathologic response. Exploratory analyses examined changes in the tumor microenvironment. Results: Twenty-four eligible patients [26 tumors, n = 22 pMMR; n = 4 mismatch repair deficient (dMMR)] were enrolled (two patients had synchronous primary tumors). Neoadjuvant BOT/BAL was safe and did not delay planned surgery in any patient. The major pathologic response rate was 41% [95% confidence interval (CI), 21%–64%] for pMMR and 100% (95% CI, 40%–100%) for dMMR colorectal cancer. BOT/BAL was associated with significant antitumor effects in the tumor microenvironment, with an increase in the density and proportion of CD8+ T cells, a reduction in tumor-infiltrating FOXP3+ regulatory T cells, and evidence of an increased immune cell–cell interaction in responding patients. Conclusions: These findings demonstrate safety, feasibility, and encouraging pathologic responses for BOT/BAL in both nonmetastatic pMMR and dMMR colorectal cancer. Tumor microenvironment remodeling suggests a robust antitumor immune response induced by immunotherapy. These data support the continued development of BOT/BAL in colorectal cancer.